Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for SNGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 6.646M
March 31, 2026 3.090M
December 31, 2025 5.292M
September 30, 2025 7.598M
June 30, 2025 1.829M
March 31, 2025 3.612M
December 31, 2024 4.118M
September 30, 2024 5.935M
June 30, 2024 3.465M
March 31, 2024 0.7684M
December 31, 2023 2.522M
September 30, 2023 4.221M
June 30, 2023 5.800M
March 31, 2023 -3.387M
December 31, 2022 -2.471M
September 30, 2022 1.032M
June 30, 2022 4.206M
March 31, 2022 6.584M
December 31, 2021 10.72M
September 30, 2021 15.05M
June 30, 2021 15.60M
March 31, 2021 17.32M
December 31, 2020 3.742M
September 30, 2020 7.406M
June 30, 2020 6.031M
Date Value
March 31, 2020 3.515M
December 31, 2019 1.457M
September 30, 2019 2.678M
June 30, 2019 3.636M
March 31, 2019 5.282M
December 31, 2018 6.280M
September 30, 2018 9.268M
June 30, 2018 2.623M
March 31, 2018 4.070M
December 31, 2017 6.320M
September 30, 2017 3.145M
June 30, 2017 3.622M
March 31, 2017 5.816M
December 31, 2016 7.397M
September 30, 2016 2.170M
June 30, 2016 0.0339M
March 31, 2016 -1.050M
December 31, 2015 -0.0183M
September 30, 2015 -0.4662M
June 30, 2015 -3.520M
March 31, 2015 -1.826M
December 31, 2014 -0.1539M
September 30, 2014 -4.276M
June 30, 2014 -4.664M
March 31, 2014 -4.106M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics